EUVIMEDEUVIMED entdecken
Crossref

Palbociclib blocks neutrophilic phosphatidylinositol 3‐kinase activity to alleviate psoriasiform dermatitis

Po-Jen Chen, Hsin-Hui Tseng, Yi-Hsuan Wang, Shu-Yen Fang, Shun-Hua Chen, Chun-Hong Chen, Sheng-Chieh Tsai, Yu-Chia Chang, Yung-Fong Tsai, Tsong-Long Hwang iD

British Journal of Pharmacology · 2023

DOI: 10.1111/bph.16080 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Pharmacology, 2023. Verfasst von Po-Jen Chen und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Research, E-DA Hospital, I-Shou University, Kaohsiung, 824410, Taiwan. Hauptthemen laut MEDLINE: Psoriasis, Dermatitis. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 66 Literaturangaben. Gefördert von: Chang Gung Memorial Hospital, Linkou, E-Da Hospital, Ministry of Science and Technology, Taiwan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Purpose Neutrophilic inflammation is a critical pathogenic factor in psoriasis. The therapeutic applicability of palbociclib, a cyclin‐dependent kinase 4 and 6 (CDK4/6) inhibitor clinically used to treat cancer, in the treatment of neutrophil‐associated psoriasis remains undefined. In this study, we evaluated the therapeutic potential and pharmacological effect of palbociclib on neutrophil‐associated psoriasiform dermatitis. Experimental Approach The anti‐inflammatory effects of palbociclib were determined in activated human neutrophils. The therapeutic feasibility of palbociclib in psoriasis was demonstrated in a mouse model of imiquimod‐induced psoriasiform dermatitis. The in vitro enzymatic assays and in silico analyses were used to identify the underlying pharmacological mechanisms. Key Results This study found that palbociclib inhibited neutrophilic inflammation, including superoxide anion generation, reactive oxygen species (ROS) formation, elastase degranulation and chemotactic responses. The mechanistic studies identified that the anti‐inflammatory effects of palbociclib involved the targeting of phosphatidylinositol 3‐kinase (PI3K) but not CDK4/6 in human neutrophils. Palbociclib preferentially targeted the p110δ catalytic subunit of PI3K and thereby blocked signalling via the PI3K/protein kinase B (Akt) pathway. Furthermore, topical application of palbociclib significantly ameliorated imiquimod‐induced psoriasiform dermatitis in mice, including psoriatic symptoms, neutrophil infiltration, Akt activation and cytokine up‐regulation. Conclusions and Implications This is the first study to demonstrate that palbociclib can potentially be used to treat neutrophil‐associated psoriasiform dermatitis through the targeting of neutrophilic PI3K activity. Our findings prompt further research to explore the potential of palbociclib and PI3K in psoriasis and other inflammatory diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PsoriasisDermatitisHumansAnimalsMiceProto-Oncogene Proteins c-aktImiquimodPhosphatidylinositol 3-KinasesInflammationAnti-Inflammatory AgentsDisease Models, AnimalPiperazinesPyridines

Stichwörter der Autor:innen

PI3Kinflammationneutrophilpalbociclibpsoriasis

Substanzen

Proto-Oncogene Proteins c-aktImiquimodPhosphatidylinositol 3-KinasesAnti-Inflammatory AgentspalbociclibPiperazinesPyridines

Autor:innen und Institutionen

  • Department of Medical Research, E-DA Hospital, I-Shou University, Kaohsiung, 824410, Taiwan.
  • Graduate Institute of Natural Products, School of Traditional Chinese Medicine, Chang Gung University, Taoyuan, 333324, Taiwan.
  • Graduate Institute of Biomedical Sciences, College of Medicine, Chang Gung University, Taoyuan, 333324, Taiwan.
  • School of Nursing, Fooyin University, Kaohsiung, 831301, Taiwan.
  • Research Center for Chinese Herbal Medicine, Graduate Institute of Health Industry Technology, College of Human Ecology, Chang Gung University of Science and Technology, Taoyuan, 333324, Taiwan.
  • Graduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung University, Taoyuan, 333324, Taiwan.

ORCID-Profile: Tsong-Long Hwang

Förderung

  • Chang Gung Memorial Hospital, Linkou
  • E-Da Hospital
  • Ministry of Science and Technology, Taiwan

Zitieren

APA

Chen, P. J., Tseng, H. H., Wang, Y. H., Fang, S. Y., Chen, S. H., Chen, C. H., Tsai, S. C., Chang, Y. C., Tsai, Y. F., & Hwang, T. L. (2023). Palbociclib blocks neutrophilic phosphatidylinositol 3‐kinase activity to alleviate psoriasiform dermatitis. British Journal of Pharmacology. https://doi.org/10.1111/bph.16080

Vancouver

Chen PJ, Tseng HH, Wang YH, Fang SY, Chen SH, Chen CH, et al. Palbociclib blocks neutrophilic phosphatidylinositol 3‐kinase activity to alleviate psoriasiform dermatitis. British Journal of Pharmacology. 2023. doi:10.1111/bph.16080

BibTeX
@article{Chen2023,
  author = {Chen, Po-Jen and Tseng, Hsin-Hui and Wang, Yi-Hsuan and Fang, Shu-Yen and Chen, Shun-Hua and Chen, Chun-Hong and Tsai, Sheng-Chieh and Chang, Yu-Chia and Tsai, Yung-Fong and Hwang, Tsong-Long},
  title = {Palbociclib blocks neutrophilic phosphatidylinositol 3‐kinase activity to alleviate psoriasiform dermatitis},
  journal = {British Journal of Pharmacology},
  year = {2023},
  doi = {10.1111/bph.16080}
}
Kostenlos starten →